Published • loading... • Updated
Wegovy Reinforces Novo Nordisk's Commitment to Obesity
Summary by Merca2.es
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The German firm Berenberg continues to rely on Novo Nordisk for the potential of Wegovy and his new generation of anti-obesity drugs, but warns that Eli Lilly’s competition and the future expiry of patents will force the company to successfully implement its ambitious innovation program. In a note signed by Kerry Holford, Berenberg maintains a recommendation to Buy with an objective price of 325 Danish kroner, compared to a quote of close to 280…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
